Does the media prefer JBIO or KROS?

In the previous week, Keros Therapeutics had 2 more articles in the media than Jade Biosciences. MarketBeat recorded 4 mentions for Keros Therapeutics and 2 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 0.20 beat Keros Therapeutics' score of 0.00 indicating that Jade Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Keros Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer KROS or RIGL?

In the previous week, Keros Therapeutics had 2 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 4 mentions for Keros Therapeutics and 2 mentions for Rigel Pharmaceuticals. Keros Therapeutics' average media sentiment score of 0.00 equaled Rigel Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rigel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to KROS or SANA?

In the previous week, Keros Therapeutics had 2 more articles in the media than Sana Biotechnology. MarketBeat recorded 4 mentions for Keros Therapeutics and 2 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 0.55 beat Keros Therapeutics' score of 0.00 indicating that Sana Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sana Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LXRX or KROS?

In the previous week, Keros Therapeutics had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 4 mentions for Keros Therapeutics and 3 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.42 beat Keros Therapeutics' score of 0.00 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Keros Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer AVTX or KROS?

In the previous week, Keros Therapeutics had 2 more articles in the media than Avalo Therapeutics. MarketBeat recorded 4 mentions for Keros Therapeutics and 2 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.75 beat Keros Therapeutics' score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Keros Therapeutics (KROS) Competitors

$11.95 +0.31 (+2.66%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$11.98 +0.03 (+0.21%)

As of 10/9/2026 06:03 PM Eastern

Compare

KROS vs. JBIO, RIGL, SANA, LXRX, and AVTX

Should you buy Keros Therapeutics stock or one of its competitors? Keros Therapeutics's main competitors and comparable companies include Jade Biosciences (JBIO), Rigel Pharmaceuticals (RIGL), Sana Biotechnology (SANA), Lexicon Pharmaceuticals (LXRX), and Avalo Therapeutics (AVTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Keros Therapeutics compare to Jade Biosciences?

Jade Biosciences (NASDAQ:JBIO) and Keros Therapeutics (NASDAQ:KROS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

71.6% of Keros Therapeutics shares are owned by institutional investors. 23.1% of Jade Biosciences shares are owned by insiders. Comparatively, 12.6% of Keros Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Jade Biosciences has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

Keros Therapeutics has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A
Keros Therapeutics	$244.06M	0.97	$87.01M	-$3.70	N/A

In the previous week, Keros Therapeutics had 2 more articles in the media than Jade Biosciences. MarketBeat recorded 4 mentions for Keros Therapeutics and 2 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 0.20 beat Keros Therapeutics' score of 0.00 indicating that Jade Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Keros Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Jade Biosciences has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -21.40% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-49.11%	-45.62%
Keros Therapeutics	-256.60%	-21.40%	-19.79%

Jade Biosciences presently has a consensus price target of $51.75, indicating a potential upside of 259.62%. Keros Therapeutics has a consensus price target of $20.50, indicating a potential upside of 71.55%. Given Jade Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Jade Biosciences is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Jade Biosciences beats Keros Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Keros Therapeutics compare to Rigel Pharmaceuticals?

Keros Therapeutics (NASDAQ:KROS) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

Rigel Pharmaceuticals has higher revenue and earnings than Keros Therapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.97	$87.01M	-$3.70	N/A
Rigel Pharmaceuticals	$294.28M	3.09	$367.02M	$16.32	3.01

In the previous week, Keros Therapeutics had 2 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 4 mentions for Keros Therapeutics and 2 mentions for Rigel Pharmaceuticals. Keros Therapeutics' average media sentiment score of 0.00 equaled Rigel Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rigel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rigel Pharmaceuticals has a net margin of 116.30% compared to Keros Therapeutics' net margin of -256.60%. Rigel Pharmaceuticals' return on equity of 22.95% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-21.40%	-19.79%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

Keros Therapeutics has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market.

Keros Therapeutics currently has a consensus target price of $20.50, indicating a potential upside of 71.55%. Rigel Pharmaceuticals has a consensus target price of $59.00, indicating a potential upside of 20.21%. Given Keros Therapeutics' higher possible upside, equities analysts plainly believe Keros Therapeutics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 12.6% of Keros Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Rigel Pharmaceuticals beats Keros Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Keros Therapeutics compare to Sana Biotechnology?

Keros Therapeutics (NASDAQ:KROS) and Sana Biotechnology (NASDAQ:SANA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

71.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 12.6% of Keros Therapeutics shares are held by company insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Keros Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.18, suggesting that its stock price is 118% more volatile than the broader market.

Keros Therapeutics currently has a consensus price target of $20.50, suggesting a potential upside of 71.55%. Sana Biotechnology has a consensus price target of $9.33, suggesting a potential upside of 234.53%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Keros Therapeutics had 2 more articles in the media than Sana Biotechnology. MarketBeat recorded 4 mentions for Keros Therapeutics and 2 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 0.55 beat Keros Therapeutics' score of 0.00 indicating that Sana Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sana Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sana Biotechnology has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -21.40% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-21.40%	-19.79%
Sana Biotechnology	N/A	-103.02%	-39.16%

Keros Therapeutics has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.97	$87.01M	-$3.70	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A

Summary

Sana Biotechnology beats Keros Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Keros Therapeutics compare to Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Keros Therapeutics (NASDAQ:KROS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Keros Therapeutics has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	15.01	-$50.34M	-$0.15	N/A
Keros Therapeutics	$244.06M	0.97	$87.01M	-$3.70	N/A

Lexicon Pharmaceuticals currently has a consensus target price of $5.70, indicating a potential upside of 239.29%. Keros Therapeutics has a consensus target price of $20.50, indicating a potential upside of 71.55%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Lexicon Pharmaceuticals is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Keros Therapeutics had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 4 mentions for Keros Therapeutics and 3 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.42 beat Keros Therapeutics' score of 0.00 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Keros Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lexicon Pharmaceuticals has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by company insiders. Comparatively, 12.6% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Lexicon Pharmaceuticals has a net margin of -147.38% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -21.40% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%
Keros Therapeutics	-256.60%	-21.40%	-19.79%

Summary

Lexicon Pharmaceuticals and Keros Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Keros Therapeutics compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Keros Therapeutics (NASDAQ:KROS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Avalo Therapeutics has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -21.40% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Keros Therapeutics	-256.60%	-21.40%	-19.79%

Avalo Therapeutics has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

Keros Therapeutics has higher revenue and earnings than Avalo Therapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$59K	12,407.62	-$78.26M	-$4.37	N/A
Keros Therapeutics	$244.06M	0.97	$87.01M	-$3.70	N/A

Avalo Therapeutics presently has a consensus price target of $45.10, indicating a potential upside of 230.40%. Keros Therapeutics has a consensus price target of $20.50, indicating a potential upside of 71.55%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Avalo Therapeutics is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by insiders. Comparatively, 12.6% of Keros Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Keros Therapeutics had 2 more articles in the media than Avalo Therapeutics. MarketBeat recorded 4 mentions for Keros Therapeutics and 2 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.75 beat Keros Therapeutics' score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Keros Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Avalo Therapeutics and Keros Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Keros Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KROS vs. The Competition

Export

Metric	Keros Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$230.79M	$3.85B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-3.23	13.62	275.30	26.16
Price / Sales	0.97	1,234.33	635.97	107.50
Price / Cash	2.57	116.56	76.38	53.09
Price / Book	0.77	17.17	11.22	6.33
Net Income	$87.01M	-$22.69M	$3.50B	$382.15M
7 Day Performance	5.19%	-1.34%	-0.89%	-1.40%
1 Month Performance	6.98%	-8.45%	-4.42%	-3.47%
1 Year Performance	-23.89%	14.02%	7.03%	1.18%

Keros Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KROS Keros Therapeutics	3.7428 of 5 stars	$11.95 +2.7%	$20.50 +71.5%	-25.9%	$230.79M	$244.06M	N/A	92	News Coverage Analyst Upgrade
JBIO Jade Biosciences	1.8842 of 5 stars	$13.77 -2.0%	$51.75 +275.8%	+53.1%	$893.54M	N/A	N/A	55
RIGL Rigel Pharmaceuticals	4.3067 of 5 stars	$46.97 -2.5%	$59.00 +25.6%	+72.8%	$890.88M	$294.28M	2.88	174	Analyst Upgrade
SANA Sana Biotechnology	3.5365 of 5 stars	$2.89 -0.7%	$9.33 +223.0%	-37.3%	$872.64M	N/A	N/A	142	Positive News
LXRX Lexicon Pharmaceuticals	2.4463 of 5 stars	$1.82 -2.9%	$5.70 +213.2%	+2.4%	$834.29M	$49.80M	N/A	81

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KROS) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Keros Therapeutics (KROS) Competitors

KROS vs. JBIO, RIGL, SANA, LXRX, and AVTX

How does Keros Therapeutics compare to Jade Biosciences?

Summary

How does Keros Therapeutics compare to Rigel Pharmaceuticals?

Summary

How does Keros Therapeutics compare to Sana Biotechnology?

Summary

How does Keros Therapeutics compare to Lexicon Pharmaceuticals?

Summary

How does Keros Therapeutics compare to Avalo Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS vs. The Competition

Keros Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Keros Therapeutics (KROS) Competitors

KROS vs. JBIO, RIGL, SANA, LXRX, and AVTX

How does Keros Therapeutics compare to Jade Biosciences?

Do institutionals & insiders believe in JBIO or KROS?

Which has more risk & volatility, JBIO or KROS?

Which has stronger valuation & earnings, JBIO or KROS?

Does the media prefer JBIO or KROS?

Is JBIO or KROS more profitable?

Do analysts prefer JBIO or KROS?

Summary

How does Keros Therapeutics compare to Rigel Pharmaceuticals?

Which has stronger earnings & valuation, KROS or RIGL?

Does the media prefer KROS or RIGL?

Is KROS or RIGL more profitable?

Which has more volatility and risk, KROS or RIGL?

Do analysts recommend KROS or RIGL?

Do institutionals and insiders believe in KROS or RIGL?

Summary

How does Keros Therapeutics compare to Sana Biotechnology?

Do insiders and institutionals believe in KROS or SANA?

Which has more volatility and risk, KROS or SANA?

Do analysts prefer KROS or SANA?

Does the media refer more to KROS or SANA?

Is KROS or SANA more profitable?

Which has stronger valuation and earnings, KROS or SANA?

Summary

How does Keros Therapeutics compare to Lexicon Pharmaceuticals?

Which has higher earnings and valuation, LXRX or KROS?

Do analysts recommend LXRX or KROS?

Does the media prefer LXRX or KROS?

Which has more risk and volatility, LXRX or KROS?

Do insiders & institutionals believe in LXRX or KROS?

Is LXRX or KROS more profitable?

Summary

How does Keros Therapeutics compare to Avalo Therapeutics?

Is AVTX or KROS more profitable?

Which has more volatility and risk, AVTX or KROS?

Which has preferable valuation and earnings, AVTX or KROS?

Do analysts recommend AVTX or KROS?

Do institutionals and insiders believe in AVTX or KROS?

Does the media prefer AVTX or KROS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS vs. The Competition

Keros Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools